Surufatinib Monotherapy for Advanced Colorectal Cancer in Later Line
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, single-center clinical study to investigate the efficacy
and safety of surufatinib monotherapy in patients with advanced colorectal cancer who failed
front-line anti-angiogenic TKI therapy.
Patients have to received at least a second-line standard therapy or cannot tolerate other
treatments, and have previously failed anti-angiogenic TKIs therapy(including but not limited
to: fruquintinib/regorafenib/anlotinib) / apatinib, and are resistant to treatment, disease
progression, intolerable toxicity or no continued benefit as assessed by investigator after
therapy).
Patients who met the eligibility criteria took surufatinib monotherapy until disease
progression, death, unacceptable toxicity, withdrawal of consent by the patient, or decision
by the treating physician that discontinuation would be in the patient's best interest. The
primary study endpoint was PFS(progression free survival).